Preliminary evidence for this presumption was gained in a study by Duinkerke and coauthors (1993) in which add-on ritanserin, a pure 5HT2 blocker devoid of antidepressive properties, improved negative symptoms in haloperidol-treated schizophrenia patients. Here, HTR2A is linked to schizophrenia.